FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar
The agency approved a higher concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Medscape Medical News
source https://www.medscape.com/viewarticle/990154?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/990154?src=rss
Comments
Post a Comment